KEY POINTS:
Wool Equities' subsidiary Keratec has gained European Union regulatory approval for three wound dressings for medical use.
Keratec and US-based partner, Keraplast Technologies, developed the dressings to target chronic wounds.
Gaining the certification would make it easier to attract partner companies, and created more certainty for Keratec's biomedical business, chief executive Elizabeth Hopkins said.
The dressings contain keratin, proteins extracted from wool which are also used in cosmetics and dietary supplements. It is a component in the body's new cell growth and in healing.
"These are the first keratin-containing medical devices to gain approval from any global regulatory body, and in achieving this milestone, Keratec and Keraplast Technologies are confirmed as the world leaders in this field," Hopkins said.
- NZPA
